Multianalyte Biomarker Panel for Ovarian Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing ovarian cancer are inadequate for early detection, as most cases are not caught in the earliest stage due to vague symptoms and the lack of an effective test for early and accurate detection.
Innovation Solution
A method involving the measurement of specific biomarker panels in bodily fluids, such as blood serum, using a multianalyte panel assay to predict and diagnose ovarian cancer, particularly for epithelial ovarian cancer, by identifying a detectable molecular signature associated with the disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used, then the diagnostic process is simple, but the detection accuracy for early-stage ovarian cancer is low
Solution Approach 1:
The patent combines multiple biomarker measurements (CA125, HE4, and other proteins) into a single integrated diagnostic assay. This multianalyte approach merges several detection functions into one test system, achieving high detection accuracy for early-stage ovarian cancer while maintaining practical clinical usability through a unified diagnostic protocol.
Solution Approach 2:
The diagnostic method serves multiple functions: it detects early-stage ovarian cancer, differentiates between malignant and benign conditions, and provides risk stratification. This multi-functional approach allows a single diagnostic system to address various clinical needs, improving overall detection accuracy across different disease stages and presentations.
2Reliability
If early-stage ovarian cancer is detected, then the survival rate increases significantly, but current methods fail to detect most early-stage cases
Solution Approach 1:
The patent focuses on detecting specific local changes in biomarker levels that are characteristic of early-stage ovarian cancer. By measuring particular proteins and their concentration ratios rather than general markers, the method achieves reliable early detection by identifying localized molecular signatures specific to the disease state.
Solution Approach 2:
The diagnostic method performs preliminary detection of ovarian cancer through biomarker measurement before clinical symptoms manifest or disease progression occurs. This preliminary action enables early intervention and treatment planning, significantly improving survival outcomes by detecting cancer at a treatable stage.
3Measurement precision
If a single biomarker test is used, then the test is simple to perform, but the sensitivity and specificity are insufficient for accurate diagnosis
Solution Approach 1:
The patent merges multiple biomarker measurements into a single integrated diagnostic assay. By simultaneously measuring CA125, HE4, and other proteins in one test system, it achieves high diagnostic accuracy with sensitivity and specificity rates of at least 85%, while maintaining practical usability through a unified testing protocol.
Solution Approach 2:
The diagnostic approach uses a composite biomarker profile rather than a single marker. It combines information from multiple proteins and their relative concentrations to create a composite diagnostic indicator, achieving superior accuracy by leveraging the complementary strengths of different biomarkers in a unified assessment.
Data Source
AI summary
Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided.